Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia.

Siedner MJ, Galar A, Guzmán-Suarez BB, Kubiak DW, Baghdady N, Ferraro MJ, Hooper DC, O'Brien TF, Marty FM.

Clin Infect Dis. 2014 Jun;58(11):1554-63. doi: 10.1093/cid/ciu182. Epub 2014 Mar 18.

2.

Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates.

Lee NY, Lee CC, Li CW, Li MC, Chen PL, Chang CM, Ko WC.

Antimicrob Agents Chemother. 2015 Dec;59(12):7558-63. doi: 10.1128/AAC.01477-15. Epub 2015 Sep 28.

3.

Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.

Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC.

Clin Infect Dis. 2013 Feb;56(4):488-95. doi: 10.1093/cid/cis916. Epub 2012 Oct 22.

PMID:
23090931
5.

Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis.

Harris PN, Wei JY, Shen AW, Abdile AA, Paynter S, Huxley RR, Pandeya N, Doi Y, Huh K, O'Neal CS, Talbot TR, Paterson DL.

J Antimicrob Chemother. 2016 Feb;71(2):296-306. doi: 10.1093/jac/dkv346. Epub 2015 Nov 4. Review.

PMID:
26542304
6.

Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy?

Hilty M, Sendi P, Seiffert SN, Droz S, Perreten V, Hujer AM, Bonomo RA, Mühlemann K, Endimiani A.

Int J Antimicrob Agents. 2013 Mar;41(3):236-49. doi: 10.1016/j.ijantimicag.2012.10.022. Epub 2013 Jan 10.

7.

Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.

Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE; Antibacterial Resistance Leadership Group.

Clin Infect Dis. 2015 May 1;60(9):1319-25. doi: 10.1093/cid/civ003. Epub 2015 Jan 13. Erratum in: Clin Infect Dis. 2015 Jul 1;61(1):143.

8.

The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae.

Tamma PD, Girdwood SC, Gopaul R, Tekle T, Roberts AA, Harris AD, Cosgrove SE, Carroll KC.

Clin Infect Dis. 2013 Sep;57(6):781-8. doi: 10.1093/cid/cit395. Epub 2013 Jun 11.

PMID:
23759352
9.

High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients.

Goethaert K, Van Looveren M, Lammens C, Jansens H, Baraniak A, Gniadkowski M, Van Herck K, Jorens PG, Demey HE, Ieven M, Bossaert L, Goossens H.

Clin Microbiol Infect. 2006 Jan;12(1):56-62.

10.

Efficacy of cefepime therapy for Enterobacter bacteraemia, with special emphasis on febrile neutropenic patients.

Lee JA, Kang CI, Joung MK, Moon SY, Chung DR, Ko KS, Peck KR, Song JH.

Scand J Infect Dis. 2010 Jul;42(6-7):557-9. doi: 10.3109/00365541003621528. No abstract available.

PMID:
20214544
11.
12.

Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.

Chopra T, Marchaim D, Veltman J, Johnson P, Zhao JJ, Tansek R, Hatahet D, Chaudhry K, Pogue JM, Rahbar H, Chen TY, Truong T, Rodriguez V, Ellsworth J, Bernabela L, Bhargava A, Yousuf A, Alangaden G, Kaye KS.

Antimicrob Agents Chemother. 2012 Jul;56(7):3936-42. doi: 10.1128/AAC.05419-11. Epub 2012 Apr 30.

13.

Treatment outcomes in patients with third-generation cephalosporin-resistant Enterobacter bacteremia.

O'Neal CS, O'Neal HR, Daniels TL, Talbot TR.

Scand J Infect Dis. 2012 Oct;44(10):726-32. Epub 2012 Jun 10.

PMID:
22681412
14.

Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.

Freeman JT, McBride SJ, Nisbet MS, Gamble GD, Williamson DA, Taylor SL, Holland DJ.

Int J Infect Dis. 2012 May;16(5):e371-4. doi: 10.1016/j.ijid.2012.01.008. Epub 2012 Mar 7.

15.

Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival.

Balkan II, Aygün G, Aydın S, Mutcalı SI, Kara Z, Kuşkucu M, Midilli K, Şemen V, Aras S, Yemişen M, Mete B, Özaras R, Saltoğlu N, Tabak F, Öztürk R.

Int J Infect Dis. 2014 Sep;26:51-6. doi: 10.1016/j.ijid.2014.05.012. Epub 2014 Jul 3.

16.

Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome.

Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Oh MD, Kim EC, Choe KW.

Clin Infect Dis. 2004 Sep 15;39(6):812-8. Epub 2004 Aug 25.

PMID:
15472813
17.

Treatment of extended-spectrum Beta-lactamase enterobacteriaceae with cefepime: the dose matters, too.

Altshuler J, Aitken SL, Guervil D, Esaian D, Papadopoulos J, Arias CA.

Clin Infect Dis. 2013 Sep;57(6):915-6. doi: 10.1093/cid/cit383. Epub 2013 Jun 19. No abstract available.

18.

Clinical characteristics and predictors of mortality in patients with Enterobacter aerogenes bacteremia.

Chang EP, Chiang DH, Lin ML, Chen TL, Wang FD, Liu CY.

J Microbiol Immunol Infect. 2009 Aug;42(4):329-35.

PMID:
19949757
19.
20.

Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC.

Rhodes NJ, Liu J, McLaughlin MM, Qi C, Scheetz MH.

Diagn Microbiol Infect Dis. 2015 Jun;82(2):165-71. doi: 10.1016/j.diagmicrobio.2015.03.005. Epub 2015 Mar 10.

PMID:
25801780

Supplemental Content

Support Center